Navigation Links
Maxygen, Inc. Announces Extension of Dutch Auction Tender Offer
Date:12/11/2009

REDWOOD CITY, Calif., Dec. 11 /PRNewswire-FirstCall/ -- Maxygen, Inc. (Nasdaq: MAXY), a biopharmaceutical company focused on the development of improved versions of protein drugs, today announced that it has extended the expiration date for its modified "Dutch Auction" tender offer to repurchase 6,557,377 shares of its common stock, which was commenced on November 13, 2009. The tender offer, which was previously scheduled to expire at 12:00 midnight, New York City time, on Friday, December 11, 2009, will be extended until 5:00 p.m., New York City time, on Wednesday, December 23, 2009. The tender offer remains subject to all previously announced terms and conditions.

As of 5:00 p.m., New York City time, on Thursday, December 10, 2009, 687,535 shares of common stock have been tendered pursuant to the offer.

IMPORTANT NOTICE: On November 13, 2009, Maxygen commenced a modified "Dutch Auction" tender offer to repurchase 6,557,377 shares of its common stock. This press release is for informational purposes only and is neither an offer to buy nor the solicitation of an offer to sell any shares of Maxygen's common stock. The tender offer is being made solely by the offer to purchase, the related letter of transmittal and other related documents that Maxygen has previously sent to its stockholders. The materials have been filed as exhibits to Maxygen's tender offer statement on Schedule TO, which was originally filed with the Securities and Exchange Commission on November 13, 2009 (as subsequently amended or supplemented to date). These tender offer materials contain important information that investors are urged to read carefully before making any decision with respect to the tender offer. Each of these documents has been or will be filed with the Securities and Exchange Commission, and investors may obtain them for free from the Securities and Exchange Commission at its website (www.sec.gov) or from Okapi Partners, the information agent for the tender offer, by directing such request to: Okapi Partners LLC, 780 Third Avenue, 30th Fl., New York, NY 10017, telephone (212) 297-0720 or toll-free (877) 285-5990.

About Maxygen

Maxygen is a biopharmaceutical company focused on developing improved versions of protein drugs through both internal development and external collaborations and other arrangements. Maxygen uses its proprietary DNA shuffling technology and extensive protein modification expertise to pursue the creation of biosuperior proteins. For more information, please visit www.maxygen.com.

SOURCE Maxygen, Inc.


'/>"/>
SOURCE Maxygen, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine technology :

1. Maxygen, Inc. Commences Dutch Auction Tender Offer to Repurchase 6,557,377 Shares of Common Stock
2. ThromboGenics Announces Start of Phase II Trial of Microplasmin for the Treatment of Age-Related Macular Degeneration (AMD)
3. Boston Scientific Announces Pricing of $2 Billion of Senior Notes
4. Genomic Health Announces Publication of Study of Oncotype DX(R) in Node-Positive Breast Cancer That Identifies Patients Who Do Not Appear to Benefit From Chemotherapy
5. RetireSafe Announces Intention to Key Vote Senator Dorgans Drug Importation Amendment (SA 2793)
6. Echo Therapeutics Announces Consulting Agreement with Hayden IR to Develop and Implement a Strategic Investor Relations Campaign
7. Neogen Corporation Announces 2nd Quarter Results
8. China Yongxin Pharmaceuticals, Inc. Announces Results for the Third Quarter Ended September 30, 2009
9. Regeneron Announces Presentation at the Deutsche Bank 2009 Biotech Boston Confab
10. Arrayit Diagnostics Announces Sponsored Research Agreement With Wayne State University and Arrayit Corporation
11. Vivakor Announces New Acquisition Strategy
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2016)...  Arkis BioSciences, a leading innovator in the ... cerebrospinal fluid treatments, today announced it has secured ... led by Innova Memphis, followed by Angel Capital ... Arkis, new financing will accelerate the commercialization of ... of its in-licensed Endexo® technology. ...
(Date:6/23/2016)... , June 23, 2016 Any dentist who ... challenges of the current process. Many of them do not ... the technical difficulties and high laboratory costs involved. And those ... offer it at such a high cost that the majority ... Dr. Parsa Zadeh , founder of Dental ...
(Date:6/23/2016)... Roche (SIX: RO, ROG; OTCQX: RHHBY) announced ... BRAHMS PCT (procalcitonin) assay as a dedicated testing solution ... this clearance, Roche is the first IVD company in ... sepsis risk assessment and management. PCT is ... levels in blood can aid clinicians in assessing the ...
Breaking Medicine Technology:
(Date:6/25/2016)... (PRWEB) , ... June 25, 2016 , ... Conventional wisdom ... of success. In terms of the latter, setting the bar too high can result ... more than just slow progress toward their goal. , Research from PsychTests.com ...
(Date:6/24/2016)... CA (PRWEB) , ... June 24, 2016 , ... Marcy was in a crisis. Her ... would lash out at his family verbally and physically. , “When something upset him, he ... he would use it. He would throw rocks at my other children and say he ...
(Date:6/24/2016)... ... June 24, 2016 , ... Comfort Keepers® of San Diego, ... and the Road To Recovery® program to drive cancer patients to and from their ... to ensure the highest quality of life and ongoing independence. Getting to and ...
(Date:6/24/2016)... , ... June 24, 2016 , ... ... is proud to recognize Dr. Barry M. Weintraub as a prominent plastic surgeon ... beautiful women in the world, and the most handsome men, look naturally attractive. ...
(Date:6/24/2016)... ... ... Venture Construction Group (VCG) sponsors Luke’s Wings 5th ... Woodmont Country Club at 1201 Rockville Pike, Rockville, Maryland, 20852. The event raised ... have been wounded in battle and their families. Venture Construction Group is a 2016 ...
Breaking Medicine News(10 mins):